These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

286 related items for PubMed ID: 23470848

  • 1. A randomized trial of candidate inactivated quadrivalent influenza vaccine versus trivalent influenza vaccines in children aged 3-17 years.
    Domachowske JB, Pankow-Culot H, Bautista M, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    J Infect Dis; 2013 Jun 15; 207(12):1878-87. PubMed ID: 23470848
    [Abstract] [Full Text] [Related]

  • 2. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years.
    Kieninger D, Sheldon E, Lin WY, Yu CJ, Bayas JM, Gabor JJ, Esen M, Fernandez Roure JL, Narejos Perez S, Alvarez Sanchez C, Feng Y, Claeys C, Peeters M, Innis BL, Jain V.
    BMC Infect Dis; 2013 Jul 24; 13():343. PubMed ID: 23883186
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of inactivated quadrivalent and trivalent influenza vaccines in children 18-47 months of age.
    Rodriguez Weber MA, Claeys C, Aranza Doniz C, Feng Y, Innis BL, Jain VK, Peeters M.
    Pediatr Infect Dis J; 2014 Dec 24; 33(12):1262-9. PubMed ID: 25386965
    [Abstract] [Full Text] [Related]

  • 4. Immunogenicity, reactogenicity, and safety of inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine in healthy adults aged ≥18 years: a phase III, randomized trial.
    Tinoco JC, Pavia-Ruz N, Cruz-Valdez A, Aranza Doniz C, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    Vaccine; 2014 Mar 14; 32(13):1480-7. PubMed ID: 24486352
    [Abstract] [Full Text] [Related]

  • 5. Immunogenicity and safety of an egg-based inactivated quadrivalent influenza vaccine (GC3110A) versus two inactivated trivalent influenza vaccines with alternate B strains: A phase Ⅲ randomized clinical trial in adults.
    Song JY, Lee J, Woo HJ, Wie SH, Lee JS, Kim SW, Kim TH, Jung SI, Noh JY, Choi WS, Cheong HJ, Kim WJ.
    Hum Vaccin Immunother; 2019 Mar 14; 15(3):710-716. PubMed ID: 30396317
    [Abstract] [Full Text] [Related]

  • 6. A Phase III randomised trial of the immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in adult and elderly subjects, assessing both anti-haemagglutinin and virus neutralisation antibody responses.
    van de Witte S, Nauta J, Montomoli E, Weckx J.
    Vaccine; 2018 Sep 25; 36(40):6030-6038. PubMed ID: 29709447
    [Abstract] [Full Text] [Related]

  • 7. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate: a phase III randomized controlled trial in children.
    Langley JM, Carmona Martinez A, Chatterjee A, Halperin SA, McNeil S, Reisinger KS, Aggarwal N, Huang LM, Peng CT, Garcia-Sicilia J, Salamanca de la Cueva I, Cabañas F, Treviño-Garza C, Rodríguez-Weber MA, de la O M, Chandrasekaran V, Dewé W, Liu A, Innis BL, Jain VK.
    J Infect Dis; 2013 Aug 15; 208(4):544-53. PubMed ID: 23847058
    [Abstract] [Full Text] [Related]

  • 8. Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults.
    Beran J, Peeters M, Dewé W, Raupachová J, Hobzová L, Devaster JM.
    BMC Infect Dis; 2013 May 20; 13():224. PubMed ID: 23688546
    [Abstract] [Full Text] [Related]

  • 9. Immunogenicity and Safety of an Inactivated Quadrivalent Influenza Vaccine in US Children 6-35 Months of Age During 2013-2014: Results From A Phase II Randomized Trial.
    Wang L, Chandrasekaran V, Domachowske JB, Li P, Innis BL, Jain VK.
    J Pediatric Infect Dis Soc; 2016 Jun 20; 5(2):170-9. PubMed ID: 26407273
    [Abstract] [Full Text] [Related]

  • 10. Immunogenicity and safety of quadrivalent versus trivalent inactivated subunit influenza vaccine in children and adolescents: A phase III randomized study.
    Vesikari T, Nauta J, Lapini G, Montomoli E, van de Witte S.
    Int J Infect Dis; 2020 Mar 20; 92():29-37. PubMed ID: 31838217
    [Abstract] [Full Text] [Related]

  • 11. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6-35 months in China.
    Hu Y, Shao M, Hu Y, Liang Q, Jia N, Chu K, Xu L, Li J, Li C, Zhu F.
    Hum Vaccin Immunother; 2020 Jul 02; 16(7):1691-1698. PubMed ID: 32347785
    [Abstract] [Full Text] [Related]

  • 12. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccines in participants >/=3 years of age: a double-blind, randomized, parallel-controlled phase III clinical trial in China.
    Wang SY, Liu SZ, Chu K, Zhao Y, Zhu FC, Hu YM, Meng FY, Li JX, Luo L, Yang JY, Liu P, Yu J.
    Expert Rev Vaccines; 2017 Nov 02; 16(11):1155-1169. PubMed ID: 28870140
    [Abstract] [Full Text] [Related]

  • 13. Immunogenicity and safety of an inactivated quadrivalent influenza vaccine in healthy adults: a phase II, open-label, uncontrolled trial in Japan.
    Tsurudome Y, Kimachi K, Okada Y, Matsuura K, Ooyama Y, Ibaragi K, Kino Y, Ueda K.
    Microbiol Immunol; 2015 Oct 02; 59(10):597-604. PubMed ID: 26272602
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the immunogenicity and safety of quadrivalent and tetravalent influenza vaccines in children and adolescents.
    Huang C, Fu X, Zhou Y, Mi F, Tian G, Liu X, Wu J, Ding C, Yan D, Li L, Yang S.
    Vaccine; 2020 Feb 05; 38(6):1332-1344. PubMed ID: 31948819
    [Abstract] [Full Text] [Related]

  • 15. Immunogenicity and safety of a cell culture-derived inactivated quadrivalent influenza vaccine (NBP607-QIV): A randomized, double-blind, multi-center, phase III clinical trial in adults and elderly subjects.
    Choi WS, Noh JY, Song JY, Cheong HJ, Wie SH, Lee JS, Lee J, Kim SW, Jeong HW, Jung SI, Kim YS, Woo HJ, Kim KH, Kim H, Kim WJ.
    Hum Vaccin Immunother; 2017 Jul 03; 13(7):1653-1660. PubMed ID: 28406746
    [Abstract] [Full Text] [Related]

  • 16. Immunogenicity and Reactogenicity of an Inactivated Quadrivalent Influenza Vaccine Administered Intramuscularly to Children 6 to 35 Months of Age in 2012-2013: A Randomized, Double-Blind, Controlled, Multicenter, Multicountry, Clinical Trial.
    Langley JM, Wang L, Aggarwal N, Bueso A, Chandrasekaran V, Cousin L, Halperin SA, Li P, Liu A, McNeil S, Mendez LP, Rivera L, Innis BL, Jain VK.
    J Pediatric Infect Dis Soc; 2015 Sep 03; 4(3):242-51. PubMed ID: 26336604
    [Abstract] [Full Text] [Related]

  • 17. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults.
    Greenberg DP, Robertson CA, Noss MJ, Blatter MM, Biedenbender R, Decker MD.
    Vaccine; 2013 Jan 21; 31(5):770-6. PubMed ID: 23228813
    [Abstract] [Full Text] [Related]

  • 18. Safety and immunogenicity of an inactivated quadrivalent influenza vaccine in children 6 months through 8 years of age.
    Greenberg DP, Robertson CA, Landolfi VA, Bhaumik A, Senders SD, Decker MD.
    Pediatr Infect Dis J; 2014 Jun 21; 33(6):630-6. PubMed ID: 24445833
    [Abstract] [Full Text] [Related]

  • 19. Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults.
    Pépin S, Donazzolo Y, Jambrecina A, Salamand C, Saville M.
    Vaccine; 2013 Nov 12; 31(47):5572-8. PubMed ID: 24016810
    [Abstract] [Full Text] [Related]

  • 20. Quadrivalent Influenza Vaccine-Induced Antibody Response and Influencing Determinants in Patients ≥ 55 Years of Age in the 2018/2019 Season.
    Ganczak M, Dubiel P, Drozd-Dąbrowska M, Hallmann-Szelińska E, Szymański K, Brydak LB.
    Int J Environ Res Public Health; 2019 Nov 14; 16(22):. PubMed ID: 31739554
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.